The Arcas Group is pleased to announce the recent article discussions of two studies conducted by the MDoutlook intelligence system. The first study, conducted in partnership with Oncology Business Review, focused on uncovering new ideas, gauging support for current proposals, and collecting opinions about how reimbursement and drug access changes may affect the cost and quality of cancer care in the US. The sheer number of comments to this survey (more than half of the sample) suggests oncologists are eager to have a voice in healthcare reform. Full results are available via this OBR article on MDoutlook.
The second study, featured in Med Ad News, highlighted the results of MDoutlook Quick Polls performed following ASCO 2009. The Arcas Group, in close consultation with members of the MDoutlook Strategy Council, selected key oncology developments presented at the ASCO Annual Meeting in Orlando. Within one week, 370 cancer treaters from 32 countries completed these Quick Polls making it the first market feedback available. Members of the MDoutlook Strategy Council believe these results validate the expected change in physician decision-making. Story and results of the Quick Poll are available via Med Ad News article on MDoutlook.
MDoutlook (www.thearcasgroup.com/mdoutlook) is an innovative proprietary, web-based intelligence resource. By offering unprecedented connectivity to 43,000 cancer treaters worldwide, MDoutlook delivers a better, more comprehensive view of the oncology marketplace for its BioPharma subscribers. To find out how MDoutlook can provide actionable insight for your commercialization strategy, please contact us at [email protected] or call +1.404.496.4136.